Pediatrix Medical Group, Inc. (MD) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$0.59	$0.63	+6.8%	—	$487.8M	—
Q1 26	$0.38	$0.44	+15.8%	—	$476.2M	—
Q4 25	$0.54	$0.5	-7.4%	—	$493.8M	—
Q3 25	$0.47	$0.67	+42.6%	—	$492.9M	—
Q2 25	$0.42	$0.53	+26.2%	—	$468.8M	—
Q1 25	$0.24	$0.33	+37.5%	—	$458.4M	—
Q4 24	$0.36	$0.51	+41.7%	—	$502.4M	—
Q3 24	$0.37	$0.44	+18.9%	—	$511.2M	—
Q2 24	$0.31	$0.34	+9.7%	—	$504.3M	—
Q1 24	$0.19	$0.2	+5.3%	—	$495.1M	—
Q4 23	$0.32	$0.32	0.0%	—	$496.4M	—
Q3 23	$0.43	$0.32	-25.6%	—	$506.6M	—
Q2 23	$0.4	$0.39	-2.5%	—	$500.6M	—
Q1 23	$0.22	$0.23	+4.5%	—	$491M	—
Q4 22	$0.49	$0.47	-4.1%	—	$513.8M	—
Q3 22	$0.54	$0.4	-25.9%	—	$489.9M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$1.99	—	—	$1.9B	—
FY24	—	-$1.15	—	—	$2B	—
FY23	—	-$0.72	—	—	$2B	—
FY22	—	$0.8	—	—	$2B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$3.2B	$3.3B	$1.7B	$1.8B	$1.7B	$1.9B	$2B	$2B	$2B	$1.9B
YoY change	+14.5%	+2.21%	-47%	+3.29%	-2.57%	+10.2%	+3.18%	+1.15%	+0.92%	-4.92%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	3.2B	3.3B	1.7B	1.8B	1.7B	1.9B	2B	2B	2B	1.9B
Cost of revenue	2.1B	2.3B	1.2B	1.3B	1.3B	1.4B	1.5B	1.6B	1.6B	1.4B
Gross profit	1B	919.6M	505M	503.1M	449.3M	513.2M	467M	421.6M	454.3M	493.7M
Gross margin	32.5%	28.3%	29.3%	28.3%	25.9%	26.9%	23.7%	21.1%	22.6%	25.8%
Research & development	—	—	—	—	—	—	—	—	—	—
Selling, general & administrative	372.6M	385.9M	232.2M	244.5M	248.9M	263.4M	231.4M	227.5M	238.4M	240.8M
Operating expenses	372.6M	385.9M	232.2M	244.5M	248.9M	263.4M	231.4M	227.5M	238.4M	240.8M
Operating income	571.7M	454.9M	248.4M	232.6M	171.9M	217.7M	200M	157.9M	183.7M	231.1M
Operating margin	18%	14%	14.4%	13.1%	9.92%	11.4%	10.1%	7.91%	9.13%	12.1%
Non-operating income, net	5.2M	5.3M	10.8M	-54.9M	-54.3M	-13.8M	-78.9M	-164.1M	-244.3M	21.3M
Pretax income	513.8M	385.7M	166.2M	58.8M	7.1M	135.2M	81.4M	-48.4M	-101.3M	216.4M
Income tax	189.2M	80.2M	44.7M	16.6M	16.7M	27.2M	18.8M	12M	-2.3M	51M
Net income	324.6M	320.4M	268.6M	-1.5B	-796.5M	130.9M	66.3M	-60.4M	-99.1M	165.4M
Net margin	10.2%	9.85%	15.6%	-84.2%	-45.9%	6.85%	3.36%	-3.03%	-4.92%	8.64%
EBITDA	664.1M	534.7M	280.5M	260.8M	202M	251.8M	237.4M	196.1M	218.3M	256.5M
EPS	3.47	3.42	3.06	-17.8	-9.31	1.52	0.8	-0.72	-1.15	1.99
Diluted EPS	3.47	3.42	2.93	-17.9	-9.55	1.52	0.79	-0.73	-1.19	1.94

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	506.6M	496.4M	495.1M	504.3M	511.2M	502.4M	458.4M	468.8M	492.9M	493.8M	476.2M	487.8M
Cost of revenue	399.7M	395.3M	400.2M	390.2M	394.3M	373.8M	355.7M	344.1M	352.5M	367.8M	363.2M	355.3M
Gross profit	106.9M	101.2M	94.9M	114.1M	116.8M	128.5M	102.6M	124.7M	140.3M	126M	113M	132.5M
Gross margin	21.1%	20.4%	19.2%	22.6%	22.9%	25.6%	22.4%	26.6%	28.5%	25.5%	23.7%	27.2%
Research & development	—	—	—	—	—	—	—	—	—	—	—	—
Selling, general & administrative	57.4M	53.1M	60.2M	56.6M	58.1M	63.6M	58.6M	55.7M	60.8M	65.7M	60.3M	61.3M
Operating expenses	57.4M	53.1M	60.2M	56.6M	58.1M	63.6M	58.6M	55.7M	60.8M	65.7M	60.3M	61.3M
Operating income	40.3M	39M	24.4M	48.8M	52.4M	58.1M	38.7M	63.7M	74M	54.7M	46.6M	65.4M
Operating margin	7.95%	7.86%	4.92%	9.67%	10.3%	11.6%	8.44%	13.6%	15%	11.1%	9.78%	13.4%
Non-operating income, net	934K	-167.8M	-5.9M	-206.2M	-17.1M	-15.1M	-1.5M	398K	22.7M	-338K	530K	-3.2M
Pretax income	30.8M	-138.8M	7.8M	-167.7M	25.2M	33.3M	28.1M	55M	87.8M	45.6M	38.8M	54M
Income tax	9.4M	-14.6M	3.8M	-14.7M	5.8M	2.8M	7.4M	15.7M	16.1M	11.9M	9.3M	14.2M
Net income	21.4M	-124.3M	4M	-153M	19.4M	30.5M	20.7M	39.3M	71.7M	33.7M	29.6M	39.8M
Net margin	4.22%	-25%	0.81%	-30.3%	3.8%	6.07%	4.52%	8.37%	14.5%	6.82%	6.21%	8.17%
EBITDA	50.1M	48.6M	35.2M	58M	59.1M	65.9M	44.4M	69.5M	81.4M	61.1M	53.4M	71.9M
EPS	0.26	-1.48	0.05	-1.84	0.23	0.35	0.24	0.45	0.85	0.41	0.36	0.5
Diluted EPS	0.26	-1.5	0.05	-1.84	0.23	0.35	0.24	0.45	0.84	0.4	0.36	0.49

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	6.2B	5B	2.9B	2.3B	2.1B	2.4B	1.2B	781.4M	1.1B	1.8B	2.1B
Enterprise value	7.9B	6.8B	4.8B	4B	2.7B	2.9B	1.8B	1.3B	1.4B	1.9B	2.3B
Shares outstanding	93.7M	93.7M	87.8M	84.2M	85.6M	86.4M	82.9M	84M	85.9M	83M	83M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	19.2	15.6	10.8	—	—	18	18.6	—	—	10.7	12.4
P/S	1.96	1.54	1.68	1.32	1.21	1.23	0.63	0.39	0.56	0.93	1.08
P/B	2.26	1.63	0.94	1.56	2.81	2.62	1.38	0.92	1.47	2.05	2.33
EV/EBITDA	11.9	12.7	17.2	15.2	13.3	11.6	7.78	6.66	6.6	7.44	8.62
EV/Sales	2.48	2.09	2.8	2.22	1.54	1.53	0.94	0.65	0.72	1	1.17
Earnings yield	5.2%	6.4%	9.27%	—	—	5.57%	5.38%	—	—	9.32%	8.06%
FCF yield	6.48%	9.69%	10.2%	14.5%	8.37%	1.89%	11.1%	13.3%	16.4%	14.2%	7.63%
PEG	—	—	—	—	—	—	—	—	—	—	1.17

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	32.5%	28.3%	29.3%	28.3%	25.9%	26.9%	23.7%	21.1%	22.6%	25.8%	27.2%
Operating margin	18%	14%	14.4%	13.1%	9.92%	11.4%	10.1%	7.91%	9.13%	12.1%	13.4%
Net margin	10.2%	9.85%	15.6%	-84.2%	-45.9%	6.85%	3.36%	-3.03%	-4.92%	8.64%	8.96%
ROE	11.8%	10.4%	8.7%	-99.9%	-106.5%	14.6%	7.44%	-7.11%	-13%	19.1%	20.4%
ROA	6.08%	5.46%	4.52%	-36.1%	-23.8%	4.81%	2.83%	-2.72%	-4.6%	7.36%	7.11%
ROIC	8.21%	7.43%	3.62%	5.37%	0%	11.8%	10.2%	11.5%	17%	17.6%	17%
Return on tangible assets	-8.8%	-8.05%	-9.55%	-132.7%	-235.1%	-39.5%	-8.81%	10.2%	27.9%	-53.6%	-40.2%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	1.31	1.18	1.31	1.35	3.49	1.97	1	1.24	1.47	1.66	1.32
Quick ratio	1.31	1.18	1.31	1.35	3.49	1.97	1	1.24	1.47	1.66	1.32
Debt / equity	0.62	0.6	0.64	1.2	2.41	1.19	0.8	0.83	0.87	0.73	0.7
Debt / assets	0.32	0.32	0.33	0.43	0.54	0.39	0.31	0.32	0.31	0.28	0.29
Net debt / EBITDA	2.47	3.33	6.87	6.18	2.85	2.3	2.59	2.67	1.44	0.53	0.81
Interest coverage	9.14	6.17	2.79	1.49	1.06	2.97	3.05	-0.15	-1.49	7.02	7.63
Effective tax rate	36.8%	20.8%	26.9%	28.2%	100%	20.1%	23.1%	0%	0%	23.6%	22.7%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	34	34.7	19.6	21.1	20.3	22.1	23.8	23.7	23.4	23.1	23.9
EPS (basic)	3.47	3.42	3.06	-17.8	-9.31	1.52	0.8	-0.72	-1.15	1.99	1.99
EPS (diluted)	3.47	3.42	2.93	-17.9	-9.55	1.52	0.79	-0.73	-1.19	1.94	2.09
Book value per share	29.5	32.7	35.2	17.8	8.74	10.4	10.7	10.1	8.91	10.4	11.1
FCF per share	4.32	5.18	3.38	4.02	2.05	0.51	1.65	1.24	2.15	3.04	2.81
Cash per share	0.71	0.75	0.54	2.16	14.4	5.64	1.24	2.12	4.06	6.02	5.1
Capex per share	0.42	0.28	0.19	0.23	0.34	0.09	0.36	0.4	0.26	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	1.23%	0.8%	0.99%	1.08%	1.66%	0.39%	1.51%	1.67%	1.09%	—	—
Capex / operating cash flow	8.8%	6.11%	17%	17.4%	12.9%	11.6%	27.3%	-307.9%	-86.3%	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$506.6M	$496.4M	$495.1M	$504.3M	$511.2M	$502.4M	$458.4M	$468.8M	$492.9M	$493.8M	$476.2M	$487.8M
YoY change	+3.41%	-3.39%	+0.83%	+0.74%	+0.9%	+1.19%	-7.42%	-7.03%	-3.58%	-1.71%	+3.89%	+4.04%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	67M	70.5M	47.4M	182.4M	1.2B	487.1M	103.1M	177.7M	348.5M	499.7M
Receivables	495.3M	504M	506.7M	434.3M	241.9M	301.8M	296.8M	272.3M	260M	229.7M
Inventory	—	—	—	—	—	—	—	—	—	—
Total current assets	587.1M	627.2M	660M	731.5M	1.5B	840.6M	428M	483.5M	639.6M	763.5M
Property, plant & equipment	290M	344M	300.9M	294.2M	308.2M	127.3M	131.9M	137.6M	70.2M	65.2M
Goodwill & intangibles	9B	9.8B	8.7B	3B	3B	3.1B	3.1B	2.8B	2.5B	2.6B
Total assets	5.3B	5.9B	5.9B	4.1B	3.3B	2.7B	2.3B	2.2B	2.2B	2.2B
Accounts payable	28.5M	34.6M	31.1M	35.4M	59.8M	36.6M	31.9M	34.6M	46.4M	37.2M
Short-term debt	22.1M	1.4M	253K	18.3M	21.2M	22.2M	36.5M	36M	33.2M	38.4M
Total current liabilities	448.9M	531.4M	502.8M	541.8M	444.3M	427.4M	427M	388.9M	434.1M	458.9M
Long-term debt	1.7B	1.9B	2B	1.8B	1.8B	1B	680.6M	665.7M	629.1M	596.2M
Total liabilities	2.6B	2.8B	2.8B	2.6B	2.6B	1.8B	1.5B	1.4B	1.4B	1.4B
Shareholders' equity	2.8B	3.1B	3.1B	1.5B	747.7M	896.7M	891.6M	849.1M	764.9M	865.9M
Total debt	1.7B	1.9B	2B	1.8B	1.8B	1.1B	717.1M	701.6M	662.3M	634.6M
Net debt	1.6B	1.8B	1.9B	1.7B	680.8M	678.4M	707.3M	628.4M	432.4M	259.4M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	124.7M	177.7M	115.5M	133.2M	220.5M	348.5M	219.2M	348.3M	463.1M	499.7M	329M	404.2M
Receivables	277.4M	272.3M	283.7M	274.2M	286.9M	260M	242.5M	239M	231.1M	229.7M	224.8M	227.6M
Inventory	—	—	—	—	—	—	—	—	—	—	—	—
Total current assets	420.5M	483.5M	426.5M	429.2M	528.2M	639.6M	491.7M	613M	717.2M	763.5M	587M	660.1M
Property, plant & equipment	147.6M	137.6M	144.6M	113.3M	98.5M	70.2M	78.1M	77.6M	74.3M	65.2M	78M	73.9M
Goodwill & intangibles	3.1B	2.8B	2.8B	2.5B	2.5B	2.5B	2.5B	2.5B	2.5B	2.6B	2.6B	2.6B
Total assets	2.3B	2.2B	2.2B	2B	2.1B	2.2B	2B	2.1B	2.2B	2.2B	2.1B	2.1B
Accounts payable	31.7M	34.6M	31.6M	32M	47.4M	46.4M	44.1M	42.1M	38.7M	37.2M	31.5M	27.8M
Short-term debt	36.7M	36M	37.4M	36.5M	36.3M	33.2M	34.3M	35.7M	37.6M	38.4M	204.3M	198.4M
Total current liabilities	350.4M	388.9M	247.3M	310.2M	373.1M	434.1M	271.1M	341M	392.5M	458.9M	442.6M	501.6M
Long-term debt	670.2M	665.7M	741.2M	661.8M	647.4M	629.1M	621M	613.8M	604.7M	596.2M	425.4M	421.5M
Total liabilities	1.4B	1.4B	1.3B	1.3B	1.3B	1.4B	1.2B	1.3B	1.3B	1.4B	1.2B	1.2B
Shareholders' equity	968M	849.1M	856.2M	706.5M	732.5M	764.9M	789.2M	833.8M	890.7M	865.9M	878.6M	881M
Total debt	706.9M	701.6M	778.7M	698.3M	683.7M	662.3M	655.3M	649.6M	642.3M	634.6M	629.7M	620M
Net debt	685.7M	628.4M	770.7M	678.9M	579.8M	432.4M	556.3M	424.8M	302.2M	259.4M	423.9M	331.1M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	324.6M	305.4M	121.5M	42.2M	-9.6M	108M	62.6M	-60.4M	-99.1M	165.4M
Depreciation & amortization	89.3M	78.9M	24.4M	25.9M	28.4M	32.1M	35.6M	36.2M	32.2M	21.8M
Stock-based compensation	34M	28.8M	36.6M	33.4M	39M	19M	16.1M	12.3M	11.9M	18M
Change in working capital	-24M	75.3M	-47.3M	52.7M	122.5M	-64.9M	15.5M	-221K	33.6M	16.4M
Operating cash flow	446M	428.2M	100.8M	110.8M	223.6M	65M	108.9M	-10.8M	-25.5M	271.1M
Capital expenditure	-39.3M	-26.1M	-17.1M	-19.3M	-28.8M	-7.5M	-29.7M	-33.3M	-22M	—
Investing cash flow	-821.2M	-553M	-84.7M	-50.2M	-58.3M	-55.4M	-57M	-48.2M	-35.4M	162K
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	-61.8M	-70.2M	-302.2M	-145.3M	-8.5M	-4.7M	-88.5M	-919K	-1.7M	-86.7M
Financing cash flow	-1.1B	-2.6B	-2.3B	-2.4B	-530.4M	-760.1M	-487.6M	-25.7M	-14.5M	-107.5M
Net change in cash	-1.5B	-2.7B	-2.2B	-2.3B	-365.1M	-750.6M	-435.6M	-84.7M	-75.4M	163.8M
Free cash flow	404.5M	485.2M	296.6M	338.4M	175.8M	44.5M	137.2M	104M	184.6M	252.6M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	21.4M	-124.3M	4M	-153M	19.4M	30.5M	20.7M	39.3M	71.7M	33.7M	29.6M	39.8M
Depreciation & amortization	9.2M	9.1M	10.3M	8.8M	6.3M	6.9M	5.3M	5.3M	5.6M	5.6M	6.1M	5.8M
Stock-based compensation	3.2M	3M	3.1M	2M	4.1M	2.7M	3.6M	3.9M	5.2M	5.3M	4.7M	5.1M
Change in working capital	36.5M	1.7M	-146.4M	75.9M	58.7M	16.2M	-151.3M	74.7M	63.8M	-8.4M	-178.5M	60.1M
Operating cash flow	72.1M	-119.2M	-129.4M	-92.2M	97.6M	69.4M	-117.7M	137.2M	137.3M	114.1M	-129.8M	125.3M
Capital expenditure	-9.2M	-9M	-5.3M	-7M	-6.3M	-3.4M	-3.3M	—	—	—	—	—
Investing cash flow	-14.1M	-12.4M	-16.2M	-12.9M	-6.7M	-1.9M	-7.5M	-2.6M	11.9M	-5M	-5.7M	7.4M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	-133K	0	-887K	-11K	-162K	-643K	-1.6M	-209K	-20.9M	-64M	-21.5M	-42.7M
Financing cash flow	370.4M	-4.7M	-14.3M	-227.7M	-3.1M	-5M	-6M	-4.3M	-28.6M	-68.6M	-27.6M	-48.2M
Net change in cash	428.4M	-136.4M	-159.9M	-332.8M	87.9M	62.5M	-131.2M	130.3M	120.7M	40.5M	-163.2M	84.5M
Free cash flow	70.8M	60.2M	-130.6M	100M	85.5M	129.6M	-120.8M	132.7M	131.9M	108.8M	-136.1M	123.9M

Pediatrix Medical Group, Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement